DDInter1042 DDInter1770
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation.
Terfenadine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Hyaluronidase
Terfenadine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lasmiditan
Terfenadine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Venlafaxine
Terfenadine {u} may lead to a major life threatening interaction when taken with {v} Crizotinib
Terfenadine {u} may lead to a major life threatening interaction when taken with {v} Citalopram
Terfenadine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine
Terfenadine may lead to a major life threatening interaction when taken with Crizotinib
Terfenadine may lead to a major life threatening interaction when taken with Citalopram